Concerning its clinical role in PAH, the only evidence available comes from the work of Bayram et al. [20], which showed that the addition of trimetazidine to standard therapy in patients with cor pulmonale (a condition characterized by pulmonary hypertension secondary to chronic lung disease) reduced oxidative stress and BNP. Here, NPPB is linked to pulmonary arterial hypertension.